Mantle Cell Lymphoma
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Loretta Nastoupil, MDVideo Insights | September 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Leah LawrenceMantle Cell Lymphoma | September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 9, 2023
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
Blood Cancers Today Staff WritersMantle Cell Lymphoma | September 8, 2023
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
Advertisement
Cecilia BrownMantle Cell Lymphoma | September 8, 2023
The patient cohort had median OS of 27 months and a five-year OS of 24.5%.
Cecilia BrownChronic Lymphocytic Leukemia | August 30, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Cailin ConnerMantle Cell Lymphoma | August 24, 2023
Researchers developed the score because no early risk-stratification system has been validated in this setting.
Cecilia BrownMantle Cell Lymphoma | August 23, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMantle Cell Lymphoma | August 22, 2023
An imaging assessment at day 30 showed that 90% of patients had a complete response in terms of systemic disease.
Leah SherwoodMantle Cell Lymphoma | July 24, 2023
With a median follow up of 41 months, the three-year PFS and OS rates were 85% and 86%, respectively.
Leah SherwoodMantle Cell Lymphoma | July 24, 2023
The single-arm, phase II clinical trial enrolled 50 previously untreated patients with a median age of 69 years.
Leah SherwoodMantle Cell Lymphoma | July 23, 2023
The trial assessed discontinuation of ibrutinib treatment in patients with indolent clinical forms of MCL.
Cecilia BrownPrint | July 19, 2023
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Leah SherwoodMantle Cell Lymphoma | June 20, 2023
Liso-cel demonstrated high ORR and CR rate that were durable and was well tolerated.
Cecilia BrownMantle Cell Lymphoma | June 20, 2023
The study included 300 patients with advanced MCL who did not have clinically significant comorbidities.
Leah SherwoodChronic Lymphocytic Leukemia | June 11, 2023
Dose reduction may be a strategy to mitigate the risk of cardiac AEs from recurring or worsening in B-cell malignancies.
Advertisement
Advertisement
Editorial Board